LEAF-led anti-cancer drug LEAF-140 preclinical study released

The results of treatment with LEAF-1401 showed that the exposure of permeitus, which was converted to pentaglutine (the main active form of permeitus), was 20 times higher than that of the approved anti-cancer drug, Alimta ®, Chinese name: Libita, and that permeyceramine itself was 30 times more exposed to the tumor than the already approved anti-cancer drug, The alimita ®, the name of the Chinesethe results of this study are presented in the form of posters:Posters s.3524-254: Exposure to the tumor with pentoglutinaphine permeitus after treatment with LEAF-1401 and PermiquecLEAF-1401 is a new generation of tumor immuno-metabolic drugs designed to destroy cancer and an abnormal carbon metabolism in the immune system, and is also a lipid regimen for gamma-L-pentaglutine-peme-mecosisThe results show that the effectiveness of gamma-L-glutamate-pemeresis is 80 times higher than that of peme-turretse in inhibiting thoracic acid synthesis enzymesIn October 2018, LEAF received positive feedback from the U.SFood and Drug Administration (FDA) after a pre-application meeting for a clinical trial of a new drug, LEAF-1401The FDA said the LEAF-1401 could be developed and registered in accordance with the 505(b) (2) new drug application routeIn addition, to meet the requirements of the 505(b) (2) registration pathway, the FDA provides guidance on how to build a "bridge" between the product and the Alimta ® (FDA approved drugs)(The original text has a cut)